Izamby

Denosumab, the active ingredient in Izamby, is a monoclonal antibody presented as a solution for injection for subcutaneous use. It treats osteoporosis in postmenopausal women, bone loss in men at high risk of fracture, prevents skeletal‑related events in patients with bone metastases from solid tumours, and is indicated for giant cell tumour of bone.

GNH USA supplies Izamby as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Izamby (denosumab) is used in conditions where bone resorption is increased, such as osteoporosis and metastatic bone disease.

- Postmenopausal osteoporosis: reduces fracture risk in women with low bone mass. - Male osteoporosis at high fracture risk: improves bone density and lowers fracture incidence. - Bone metastases from solid tumours: prevents skeletal‑related events such as pathologic fractures and spinal cord compression. - Giant cell tumour of bone: reduces tumour progression and need for surgery.

Common and serious adverse reactions have been reported with denosumab therapy.

Common Side Effects: - Injection site reactions: pain, redness, or swelling at the injection site. - Musculoskeletal pain: aches in joints or muscles. - Upper respiratory infections: symptoms of cold or sinusitis. - Dermatologic reactions: rash or eczema.

Serious or Rare Side Effects: - Hypocalcemia: low blood calcium levels, potentially symptomatic. - Osteonecrosis of the jaw (ONJ): exposed bone in the jaw region. - Atypical femur fractures: unusual fractures of the thigh bone. - Severe hypersensitivity: anaphylaxis or severe skin reactions.

Before initiating therapy, several safety considerations should be reviewed.

- Calcium and vitamin D supplementation: ensure adequate intake to reduce hypocalcemia risk. - Renal impairment: monitor calcium levels and adjust therapy as needed. - Dental procedures: obtain dental evaluation before starting therapy to lower ONJ risk. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Concomitant medications: review for drugs affecting calcium metabolism. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab may interact with other agents that influence calcium balance or bone metabolism.

Major Interactions (Avoid): - Calcium or vitamin D supplements taken within 4 hours of injection: may reduce absorption. - Bisphosphonates administered concurrently: increased risk of severe hypocalcemia.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine): may affect infection risk. - Anticonvulsants (e.g., phenytoin): can alter calcium metabolism. - Hormone replacement therapy: may influence bone turnover. - Chemotherapy agents: monitor for additive bone effects.